View Older Stories
-
Cantor Fitzgerald Upgrades uniQure BV (QURE) to Overweight
-
uniQure BV (QURE) PT Raised to $71 at Stifel
-
Barclays Comments on uniQure BV (QURE) Amid 66% Gain: 'a major positive'
-
uniQure (QURE) to resume trading at 7:35 a.m.
-
ClearPoint Neuro stock surges on peer's FDA approval plan
-
uniQure plans BLA submission for Huntington's therapy in Q3 2026
-
FDA Commissioner Marty Makary is resigning - Politico reporter on X
-
uniQure (QURE) Tops Q1 EPS by 2c
-
uniQure plans UK regulatory filing for Huntington's disease gene therapy
-
Mizuho Upgrades uniQure BV (QURE) to Outperform, Raise PT to $35
-
uniQure BV (QURE) PT Raised to $31 at Chardan
-
Truist on Head of CBER at FDA Exit: 'we anticipate a positive stock reaction for IRON CAPT RGNX QURE'
-
Mizuho's Jared Holz: 'We still like the sector, despite some recent setbacks like QURE and others'
-
Stifel: 'Prasad is Out, QURE is on the Map, and Rare Disease Has Political Tailwinds'
-
Wells Fargo Upgrades uniQure BV (QURE) to Overweight
-
RBC Capital Upgrades uniQure BV (QURE) to Outperform
-
TD Cowen Reiterates Buy Rating on uniQure BV (QURE)
-
Wells Fargo Downgrades uniQure BV (QURE) to Equal Weight
-
Mizuho Downgrades uniQure BV (QURE) to Neutral
-
uniQure BV (QURE) PT Lowered to $35 at Leerink Partners
-
RBC Capital Downgrades uniQure BV (QURE) to Sector Perform, Lowers PT to $11
-
uniQure BV (QURE) PT Lowered to $14 at Stifel on FDA uncertainty
-
Cantor Fitzgerald Downgrades uniQure BV (QURE) to Neutral following FDA recommendation
-
Stifel Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure faces FDA hurdle for Huntington's disease gene therapy
-
RBC Capita on uniQure BV (QURE): 'The Commissioner's comments are clearly disappointing'
-
Stifel: 'We can see why QURE shares are lower on CNBC comments from FDA'
-
UniQure stock tumbles on FDA comments about gene therapy trial
-
Wolfe Research Starts uniQure BV (QURE) at Peerperform
-
Options with increasing option implied volatility: MSTU XXRP ETHU QURE MSTZ BITX
-
uniQure reports sustained enzyme activity in Fabry disease gene therapy trial
-
uniQure (QURE) call put ratio 5.8 calls to 1 put with a focus on March 15 puts and April 70 calls
-
H.C. Wainwright Reiterates Buy Rating on uniQure BV (QURE)
-
uniQure (QURE) Reiterated at Overweight by Cantor Fitzgerald: FDA Feedback Key
-
uniQure (QURE) spreader of 6K contracts of April 30 and 40 calls
-
uniQure schedules FDA meeting on Huntington's therapy approval
-
uniQure BV (QURE) PT Lowered to $33 at Mizuho
-
uniQure receives FDA feedback on Huntington's disease gene therapy
-
William Blair Reiterates Market Perform Rating on uniQure BV (QURE)
-
uniQure BV (QURE) PT Lowered to $50 at Stifel
-
uniQure BV (QURE) PT Lowered to $60 at Leerink Partners
-
uniQure (QURE) Misses Q3 EPS by 47c
-
Raymond James on Biohaven Pharmaceutical Holding (BHVN): 'Meaningful Value Remains', 'Sticking with it'
-
uniQure BV (QURE) PT Lowered at RBC Capital After a 'Disappointing Regulatory Update'
-
uniQure BV (QURE) PT Lowered to $70 at H.C. Wainwright, maintained as Top Pick
-
William Blair Downgrades uniQure BV (QURE) to Market Perform
-
Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
-
uniQure (QURE) halted on volatility
-
Raymond James on Biohaven (BHVN) Amid News Shock: 'QURE Sympathy Move Seems Misplaced'
-
Biohaven Pharma (BHVN) Weakness May Be Tied to uniQure (QURE) Setback in Huntington's Disease

